SCHEDULE: Intracoastal Capital Boosts Processa Stake to 9.99%

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Processa Pharmaceuticals, Inc. through a warrant.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (the "Reporting Persons") collectively hold beneficial ownership of 2,907,250 shares of Processa Pharmaceuticals, Inc. common stock.
• This ownership represents 9.99% of the company's common stock.
• The beneficial ownership is primarily derived from an Intracoastal Warrant, which allows for the exercise of up to 5,000,000 shares.
• The Intracoastal Warrant contains a blocker provision, limiting the holder's right to exercise if it would result in beneficial ownership exceeding 9.99% of the common stock.
• The percentage of class is calculated based on 26,194,356 shares of common stock outstanding as of June 18, 2025, as reported by the Issuer, plus the 2,907,250 shares issuable upon exercise of the Intracoastal Warrant.
• The Reporting Persons share both voting and dispositive power over the 2,907,250 beneficially owned shares.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the company's operational or financial performance. It simply reports a significant stake by an investor group.

Positives

• Increased beneficial ownership by an institutional investor group, potentially signaling confidence in the company's long-term prospects.
• The Reporting Persons have shared voting and dispositive power over the 2,907,250 shares, indicating a coordinated investment approach.

Negatives

• No specific negative financial or operational details are disclosed in this beneficial ownership filing.

Risks

• The beneficial ownership is primarily derived from a warrant, meaning the shares are not yet fully issued and are subject to the terms of the warrant, including a 9.99% blocker provision that prevents immediate exercise beyond this threshold.

Future Outlook

NA

Industry Context

This filing reflects an investment by a capital group in a pharmaceutical company, a common occurrence in the biotech and pharma sectors where strategic investments can precede or accompany significant clinical or regulatory milestones.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes. Potential for increased investor confidence due to institutional involvement.
• Company Management: Awareness of a significant shareholder group that holds a near-10% stake, which could influence future strategic decisions or engagement.

Key Dates

Keywords

Processa Pharmaceuticals, Intracoastal Capital, Mitchell Kopin, Daniel Asher, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Pharmaceutical, Investment